Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM80YI7)

• Drug Name: citric acid Drug Info
• Synonyms: Citric acid; 77-92-9; Citric acid, anhydrous; citrate; Citro; Anhydrous citric acid; Aciletten; Citretten; Chemfill; Hydrocerol A; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-; Kyselina citronova; 2-hydroxy-1,2,3-propanetricarboxylic acid; 2-Hydroxytricarballylic acid; Citric acid anhydrous; Caswell No 221C; F 0001 (polycarboxylic acid); 3-Carboxy-3-hydroxypentane-1,5-dioic acid; 2-Hydroxypropanetricarboxylic acid; beta-Hydroxytricarballylic acid; FEMA Number 2306; K-Lyte

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 311
  ChEBI ID: CHEBI:30769
  CAS Number: CAS 77-92-9
  TTD Drug ID: DM80YI7

Molecule-Related Drug Atlas

Drug(s) Targeting Polycystic kidney disease 2-like 1 (TRPP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
benzamil	DM57SVW	Discovery agent	N.A.	Investigative	[5]
flufenamate	DMN8AP0	Discovery agent	N.A.	Investigative	[5]
malic acid	DMU3O5H	Discovery agent	N.A.	Investigative	[3]
phenamil	DMJLUFM	Discovery agent	N.A.	Investigative	[5]

Drug(s) Targeting Transient receptor potential cation channel V4 (TRPV4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
phorbol 12-myristate 13-acetate	DMJWD62	Acute myeloid leukaemia	2A60	Phase 2	[6]
GSK2798745	DM7V96W	Heart failure	BD10-BD13	Phase 2	[7]
4-Pyridin-2-yl-piperazine-1-carboxylic acid amide	DMFC8Q4	Discovery agent	N.A.	Investigative	[8]
Pyrrolidin-1-yl-thiourea	DMYNZXC	Discovery agent	N.A.	Investigative	[8]
CAPSAZEPINE	DM4ATCI	Discovery agent	N.A.	Investigative	[9]
SC-0030	DMD2WEQ	Discovery agent	N.A.	Investigative	[10]
bisandrographolide	DMRSKGC	Discovery agent	N.A.	Investigative	[11]
GSK1016790A	DMDHZR1	Discovery agent	N.A.	Investigative	[12]
GSK2193874	DMY2XV3	Discovery agent	N.A.	Investigative	[13]
RN1734	DMA3ZXM	Discovery agent	N.A.	Investigative	[14]

Drug(s) Targeting Candida Cytochrome P450 51 (Candi ERG11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[15]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[15]
Posaconazole	DMUL5EW	Aspergillosis	1F20	Approved	[16]
Ketoconazole	DMPZI3Q	Blastomycosis	1F22	Approved	[17]
Miconazole	DMPMYE8	Cutaneous candidiasis	1F23.14	Approved	[15]
Oxiconazole	DME7KRM	Tinea corporis	1F28.Y	Approved	[18]
Fluconazole	DMOWZ6B	Cryptococcal meningitis		Approved	[15]
Terconazole	DMJ13KI	Candidiasis	1F23	Approved	[19]
Bifonazole	DM3KN7V	Fungal infection	1F29-1F2F	Approved	[20]
Tioconazole	DMNYPGS	Onychomycosis	EE12.1	Approved	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Candida Cytochrome P450 51 (Candi ERG11)	TTTSOUD	CP51_CANAL	Binder	[2]
Polycystic kidney disease 2-like 1 (TRPP2)	TTAHD89	PK2L1_HUMAN	Activator	[3]
Transient receptor potential cation channel V4 (TRPV4)	TTKP2SU	TRPV4_HUMAN	Activator	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2478).
• [2] Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative. Antimicrob Agents Chemother. 2004 Apr;48(4):1256-71.
• [3] Transient receptor potential family members PKD1L3 and PKD2L1 form a candidate sour taste receptor. Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12569-74.
• [4] Impaired pressure sensation in mice lacking TRPV4. J Biol Chem. 2003 Jun 20;278(25):22664-8.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 505).
• [6] Activation of TRPV4 channels (hVRL-2/mTRP12) by phorbol derivatives. J Biol Chem. 2002 Apr 19;277(16):13569-77.
• [7] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [8] N-4-methansulfonamidobenzyl-N'-2-substituted-4-tert-butyl-benzyl thioureas as potent vanilloid receptor antagonistic ligands. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1693-6.
• [9] Chain-branched acyclic phenethylthiocarbamates as vanilloid receptor antagonists. Bioorg Med Chem Lett. 2003 May 5;13(9):1549-52.
• [10] Novel non-vanilloid VR1 antagonist of high analgesic effects and its structural requirement for VR1 antagonistic effects. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4389-93.
• [11] Bisandrographolide from Andrographis paniculata activates TRPV4 channels. J Biol Chem. 2006 Oct 6;281(40):29897-904.
• [12] N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part I. J Pharmacol Exp Ther. 2008 Aug;326(2):432-42.
• [13] An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure. Sci Transl Med. 2012 Nov 7;4(159):159ra148.
• [14] Identification and characterization of novel TRPV4 modulators. Biochem Biophys Res Commun. 2009 Nov 20;389(3):490-4.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [16] A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6.
• [17] Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
• [18] Antifungal agents: mechanisms of action. Trends Microbiol. 2003 Jun;11(6):272-9.
• [19] Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9.
• [20] Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7.
• [21] Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):261-6.